TME Pharma
 | This article may rely excessively on sources too closely associated with the subject, potentially preventing the article from being verifiable and neutral. (December 2018) |
 | |
| Company type | Aktiengesellschaft |
|---|---|
| Founded | 1997 |
| Headquarters | Berlin, Germany |
Key people |
|
Number of employees | 10 (2017)[1] |
| Website | www.noxxon.com |
Noxxon Pharma is a biotechnology company founded in 1997 in Berlin, Germany and is focused on improving cancer treatment by targeting the tumor microenvironment. Noxxon Pharma N.V. is listed on Euronext Growth, Paris (ALNOX). The company is a member of the German Association of Research-Based Pharmaceutical Companies, Verband forschender Arzneimittelhersteller (vfa).
Noxxon Pharma develops drugs using technology yielding L-RNA molecules, which are of mirror-image configuration compared to natural occurring D-RNA molecules. The company calls these agents Spiegelmers,[2][3] from Spiegel, the German word for "mirror."
The L-RNA are resistant to the natural RNA nuclease enzymes.[4]
Products
While no Spiegelmer is on the market yet, some candidates are in clinical trials.
A Spiegelmer (NOX-A12, olaptesed pegol) is under development as a combination therapy for a number of cancer indications. NOX-A12 targets CXCL12 (C-X-C Chemokine Ligand 12), a key chemokine protein. Favorable results were reported in October 2018 during the 4th CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference in New York, NY, USA.[5][6][7][8]
A different Spiegelmer (NOX-E36, emapticap pegol) has been tested for the treatment of a progressive kidney disease in diabetics, Diabetic nephropathy.[9] Favorable results were reported in June 2014 in a company press release.[10] NOX-E36 targets MCP-1, also called CCL2.[4]
A third Spiegelmer (NOX-H94, lexaptepid pegol) has been in a clinical trial for the treatment of Anemia of chronic disease.[11][12]
References
- ^ Investors. Noxxon.com. Retrieved on 2018-02-14.
- ^ Vater A, Klussmann S (March 2003). "Toward third-generation aptamers: Spiegelmers and their therapeutic prospects". Curr Opin Drug Discov Dev. 6 (2): 253–61. PMID 12669461.
- ^ Eulberg D; et al. (2006), "Spiegelmers for Therapeutic Applications", The Aptamer Handbook (in German), WILEY-VCH, pp. 417–42, ISBN 3-527-31059-2
- ^ a b "News Review: Aram Mangasarian, Noxxon Pharma AG". pharmatelevision.com. Archived from the original on 2013-05-24. Retrieved 2013-07-16.
- ^ Clinical trial number NCT03168139 for "Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic Cancer" at ClinicalTrials.gov
- ^ Clinical trial number NCT01521533 for "NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma" at ClinicalTrials.gov
- ^ Clinical trial number NCT01486797 for "NOX-A12 in Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia" at ClinicalTrials.gov
- ^ "Noxxon Presents Top-Line Data from Nox-A12 Monotherapy Part of Ongoing Metastatic Colorectal and Pancreatic Cancer Trial" (PDF) (Press release). Noxxon. October 2, 2018.
- ^ Clinical trial number NCT01547897 for "NOX-E36 in Patients With Type 2 Diabetes Mellitus and Albuminuria" at ClinicalTrials.gov
- ^ "Noxxon's Emapticap Pegol Study Selected for Late Breaking Clinical Trials Symposium during ERA-EDTA Conference" (PDF) (Press release). Noxxon. June 2, 2014.
- ^ Clinical trial number NCT01691040 for "Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Cancer" at ClinicalTrials.gov
- ^ Schwoebel F, et al. (March 2013). "The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys". Blood. 121 (12): 2311–5. doi:10.1182/blood-2012-09-456756. PMC 3606066. PMID 23349391.